IFNAR2 and systemic lupus erythematosus: Monoclonal antibodies directly inhibiting Type I IFN (sifalimumab, rontalizumab, MEDI-546, AIA122), blocking of interferon receptor (anifrolumab) and stimulation of endogenous production of antibodies to Type I IFN by interferon alpha kinoid are promising strategies in the management of lupus and other autoimmune diseases.